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Interchangeability of light 
and virtual microscopy 
for histopathological evaluation 
of prostate cancer
Renata Zelic1*, Francesca Giunchi2, Luca Lianas3, Cecilia Mascia3, Gianluigi Zanetti3,10, 
Ove Andrén4, Jonna Fridfeldt4, Jessica Carlsson4, Sabina Davidsson4, Luca Molinaro5, 
Per Henrik Vincent6,7, Lorenzo Richiardi8, Olof Akre6,7, Michelangelo Fiorentino9 & 
Andreas Pettersson1
Virtual microscopy (VM) holds promise to reduce subjectivity as well as intra- and inter-observer 
variability for the histopathological evaluation of prostate cancer. We evaluated (i) the repeatability 
(intra-observer agreement) and reproducibility (inter-observer agreement) of the 2014 Gleason 
grading system and other selected features using standard light microscopy (LM) and an internally 
developed VM system, and (ii) the interchangeability of LM and VM. Two uro-pathologists reviewed 
413 cores from 60 Swedish men diagnosed with non-metastatic prostate cancer 1998–2014. Reviewer 
1 performed two reviews using both LM and VM. Reviewer 2 performed one review using both 
methods. The intra- and inter-observer agreement within and between LM and VM were assessed 
using Cohen’s kappa and Bland and Altman’s limits of agreement. We found good repeatability and 
reproducibility for both LM and VM, as well as interchangeability between LM and VM, for primary 
and secondary Gleason pattern, Gleason Grade Groups, poorly formed glands, cribriform pattern 
and comedonecrosis but not for the percentage of Gleason pattern 4. Our findings confirm the non-
inferiority of VM compared to LM. The repeatability and reproducibility of percentage of Gleason 
pattern 4 was poor regardless of method used warranting further investigation and improvement 
before it is used in clinical practice.
The Gleason score is a powerful prognostic factor in prostate  cancer1,2. Gleason grading is based on subjective 
histopathological evaluation inevitably leading to inter-observer  variability3–11. To minimize the inter-observer 
variability and to reach consensus in controversial areas relating to the Gleason grading system, the International 
Society of Urological Pathology (ISUP) has performed two major revisions: one in  200512, and one in  201413. 
In the ISUP 2014 revision, it was, among other things, recommended that cribriform pattern, fused glands 
and poorly formed glands should be graded as Gleason pattern 4, presence of comedonecrosis and single cells 
indicates Gleason pattern  513, and that percentage of Gleason pattern 4 should be recorded for all Gleason score 
7  cores14. The inter-observer agreement for these and other histopathological features has so far been little 
 investigated15–17.
Traditionally, the histopathological evaluation has been conducted using light microscopy (LM). Advance-
ments in whole slide imaging and software development have led to the development of digital pathology and 
virtual microscopy (VM)18,19. Although digital pathology and VM are now being introduced in clinical practice, 
it has hitherto mostly been used for educational purposes, quality assurance, research or for second  opinion20–22. 
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VM, with or without artificial intelligence features, holds promise to minimize subjectiveness in the slide inter-
pretation, improve the inter-observer agreement, and reduce the review time. Interchangeability of LM and VM 
has been demonstrated for primary and secondary Gleason pattern, Gleason score, tumour length and perineural 
 invasion6,23–25, but not for different Gleason related characteristics (i.e. poorly formed glands, cribriform pattern, 
comedonecrosis and the percentage of Gleason pattern 4) or for other histopathological characteristics.
As part of an ongoing project, ProMort, which aims at identifying histopathological and molecular markers 
of lethal prostate  cancer26, we have developed a new VM system. The present study was conducted to confirm 
that the study pathologists could use our VM system instead of standard LM for the histopathological review in 
ProMort. We evaluated the interchangeability of LM and VM by estimating the intra- and inter-method repeat-
ability (i.e., intra-observer agreement) and reproducibility (i.e., inter-observer agreement) for not only the ISUP 
2014 Gleason system but also for several less commonly investigated histopathological features.
Results
In total, 413 cores on 352 slides belonging to 60 cases were reviewed by both reviewers using both LM and VM. 
Baseline characteristics of the study population are shown in Table 1. Most men were diagnosed prior to 2006 
(63%), had Gleason score ≤ 7 (70%), T3 clinical tumor stage (42%), a mean age of 69 years and a mean PSA of 
14 ng/ml at diagnosis. The distribution of the characteristics recorded on the core level using LM and VM are 
reported in Table 2. The distribution of the characteristics recorded on the slide level and the case level summaries 
are shown in Supplementary Table S1 and S2. 
Repeatability. Intra‑method, intra‑observer agreement. For both the core length and tumour length, the 
limits of agreement were narrower for VM than for LM, indicating better repeatability using VM (Supplementary 
Figs. S1 and S2). The agreement for the Gleason related characteristics was similar for LM vs. VM (Fig. 1), rang-
ing from substantial to almost perfect (primary Gleason pattern: κwLM = 0.79 vs. κwVM = 0.84; secondary Gleason 
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Light microscopy Virtual microscopy
Reviewer 1.1 Reviewer 1.2 Reviewer 2 Reviewer 1.1 Reviewer 1.2 Reviewer 2
N (%) N (%) N (%) N (%) N (%) N (%)
Biopsy core length (mm)
Mean (SD) 10.54 (3.73) 10.38 (3.73) 10.38 (3.68) 11.15 (3.95) 11.23 (4.00) 10.81 (3.92)
Positive core
No 155 (37.53) 156 (37.77) 156 (37.77) 156 (37.77) 150 (38.74) 166 (40.19)
Yes 258 (62.47) 257 (62.23) 257 (62.23) 257 (62.23) 253 (61.26) 247 (59.81)
Tumor length (mm)
Mean (SD) 7.59 (4.36) 7.27 (4.33) 7.62 (4.42) 6.85 (4.73) 7.04 (4.71) 6.95 (4.70)
Primary Gleason pattern
3 82 (31.78) 90 (35.02) 79 (30.74) 92 (35.80) 56 (33.60) 89 (36.03)
4 161 (62.40) 165 (64.20) 152 (59.14) 155 (60.31) 158 (62.45) 153 (61.94)
5 15 (5.81) 2 (0.787) 26 (10.12) 10 (3.89) 10 (3.95) 5 (2.02)
Secondary Gleason pattern
3 68 (26.36) 70 (27.24) 64 (24.90) 76 (29.57) 70 (27.67) 67 (27.13)
4 127 (49.22) 131 (50.97) 113 (43.97) 129 (50.19) 119 (47.04) 108 (43.72)
5 63 (24.42) 56 (21.79) 80 (31.13) 52 (20.23) 64 (25.30) 72 (29.15)
Gleason score
6 47 (18.22) 56 (21.79) 45 (17.51) 58 (22.57) 50 (19.76) 55 (22.27)
7 56 (21.71) 48 (18.68) 53 (20.62) 52 (20.23) 55 (21.74) 46 (18.62)
8 82 (31.78) 95 (36.96) 61 (23.74) 85 (33.07) 78 (30.83) 69 (27.94)
9 68 (26.36) 58 (22.57) 90 (35.02) 62 (24.12) 66 (26.09) 77 (31.17)
10 5 (1.94) – 8 (3.11) 4 (1.58)
Gleason Grade groups
1 47 (18.22) 56 (21.79) 45 (17.51) 58 (22.57) 50 (19.76) 55 (22.27)
2 35 (13.57) 34 (13.23) 34 (13.23) 34 (13.23) 35 (13.83) 34 (13.77)
3 21 (8.14) 14 (5.45) 19 (7.39) 18 (7.00) 20 (7.91) 12 (4.86)
4 82 (31.78) 95 (36.96) 61 (23.74) 85 (33.07) 78 (30.83) 69 (27.94)
5 73 (28.29) 58 (22.57) 98 (38.13) 62 (24.12) 70 (27.67) 77 (31.17)
Percentage of Gleason pattern 4
Mean (SD) 43.75 (29.16) 35.94 (24.90) 42.92 (25.37) 29.63 (22.32) 31.46 (22.35) 26.07 (18.28)
Perineural invasion
No 200 (77.52) 218 (84.82) 198 (77.04) 213 (83.53) 205 (81.35) 209 (84.96)
Yes 58 (22.48) 39 (15.18) 59 (22.96) 42 (16.47) 47 (18.65) 37 (15.04)
Missing – – – 2 1 1
Intraductal carcinoma
No 256 (99.22) 252 (98.05) 243 (94.55) 248 (97.25) 248 (98.41) 241 (97.97)
Yes 2 (0.78) 5 (1.95) 14 (5.45) 7 (2.75) 4 (1.59) 5 (2.03)
Missing – – – 2 1 1
Ductal carcinoma
No 258 (100.00) 257 (100.00) 256 (99.61) 255 (100.00) 252 (100.00) 246 (100.00)
Yes 0 0 1 (0. 39) 0 0 0
Missing – – – 2 1 1
Poorly formed glands
No 97 (38.13) 78 (32.28) 102 (40.49) 77 (30.20) 72 (28.57) 96 (39.02)
Yes 161 (61.87) 179 (67.72) 155 (59.51) 178 (69.80) 180 (71.43) 150 (60.98)
Missing – – – 2 1 1
Cribriform pattern
No 145 (56.20) 155 (60.31) 130 (50.58) 153 (60.00) 151 (59.92) 148 (60.16)
Yes 113 (43.80) 102 (39.69) 127 (49.42) 102 (40.00) 101 (40.08) 98 (39.84)
Missing – – – 2 1 1
Hypernephroid pattern
No 254 (98.45) 257 (100.00) 248 (96.50) 255 (100.00) 252 (100.00) 246 (100.00)
Yes 4 (1.55) 0 9 (3.50) 0 0 0
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pattern: κwLM = 0.67 vs. κwVM = 0.66; GGs: κwLM = 0.85 vs. κwVM = 0.84) (Supplementary Fig. S3). The agreement 
for comedonecrosis and perineural invasion was similar using the two methods, while it was higher on VM vs. 
LM for cribriform pattern, poorly formed glands, mucinous and intraductal carcinoma and for all slide level 
characteristics (Supplementary Figs. S3 and S4), indicating either comparable or better repeatability on VM vs. 
LM (Fig. 1). The agreement for the percentage of Gleason pattern 4 was overall poor, but somewhat better on 
VM vs. LM in terms of average differences and width of limits of agreement (Table 3, Supplementary Fig. S5).
Reproducibility. Intra‑method, inter‑observer agreement. For both the core length and tumour length, the 
average inter-observer difference was close to zero for both LM and VM, with narrower limits of agreement for 
VM (Supplementary Figs. S6 and S7), indicating good reproducibility using both methods. The agreement for 
the Gleason related characteristics was similar for the two methods (Fig. 2), ranging from moderate/substantial 
to almost perfect (primary Gleason pattern: κwLM = 0.72–0.89 vs. κwVM = 0.78–0.80; secondary Gleason pattern: 
κwLM = 0.58–0.74 vs. κwVM = 0.67–0.68; GGs: κwLM = 0.80–0.89 vs. κwVM = 0.83) (Supplementary Fig. S8), indicating 
good reproducibility using both methods. The agreement for the remaining characteristics was similar for the 
two methods, except for mucinous carcinoma, perineural invasion, high-grade prostatic intraepithelial neo-
plasia (HGPIN) and chronic inflammation where it was higher on LM (Fig. 2, Supplementary Figs. S8 and S9), 
indicating better reproducibility using LM. The agreement for the percentage of Gleason pattern 4 was overall 
Light microscopy Virtual microscopy
Reviewer 1.1 Reviewer 1.2 Reviewer 2 Reviewer 1.1 Reviewer 1.2 Reviewer 2
N (%) N (%) N (%) N (%) N (%) N (%)
Mucinous carcinoma
No 252 (97.67) 253 (98.83) 243 (94.55) 251 (98.43) 247 (98.02) 243 (98.78)
Yes 6 (2.33) 3 (1.17) 14 (5.45) 4 (1.57) 5 (1.98) 1.22
Missing – 1 – 2 1 1
Comedonecrosis
No 246 (95.35) 247 (96.11) 233 (90.66) 242 (94.90) 238 (94.47) 233 (94.72)
Yes 12 (4.65) 10 (3.89) 24 (9.34) 13 (5.08) 14 (5.53) 13 (5.28)
Missing – – – 2 1 1
Table 2.  Histopathological characteristic evaluated on the core level for the 413 cores which were evaluated 
by both reviewers using both the light and virtual microscopy. N sample size; SD standard deviation; Reviewer 
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Figure 1.  Repeatability plot for all characteristics evaluated on the core and slide level. Note: Intra-observer 
agreement refers to the agreement of the Reviewer 1.1 vs. Reviewer 1.2. LM light microscopy; VM virtual 
microscopy; GGs Gleason Grade Groups; GS Gleason score; PNI perineural invasion; PAH postatrophic 
hyperplasia; HGPIN high-grade prostatic intraepithelial neoplasia; infl Inflammation; ca carcinoma.
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Table 3.  Intra- and inter-method, intra- and inter-observer agreement for the percentage of Gleason pattern 4, 
evaluated on the core level. N sample size; SD standard deviation; Light 1.1, First review by Reviewer 1 on light 
microscopy; Light 1.2, Second review by Reviewer 1 on light microscopy; Virtual 1.1, First review by Reviewer 
1 on virtual microscopy; Virtual 1.2, Second review by Reviewer 1 on virtual microscopy; Light 2, Reviewer 2 
on light microscopy; Virtual 2, Reviewer 2 on virtual microscopy.
N
Difference
Limits of agreementMean SD Median Min Max
Intra-method agreement
Intra-observer agreement
 Light 1.1 vs. Light 1.2 40 10.23 27.30 10 − 60 80 − 43.29, 63.74
 Virtual 1.1 vs. Virtual 1.2 42 − 2.99 17.72 − 0.13 − 56.71 28.24 − 37.71, 31.74
Inter-observer agreement
 Light 1.1 vs. Light 2 47 − 3 20.05 0 − 80 40 − 42.29, 36.29
 Light 1.2 vs. Light 2 36 − 6.53 24.84 − 2.5 − 70 60 − 55.21, 42.15
 Virtual 1.1 vs. Virtual 2 37 1.20 19.40 3.49 − 48.95 38.82 − 36.82, 39.23
 Virtual 1.2 vs. Virtual 2 37 4.82 22.68 3.55 − 50.06 51.26 − 39.63, 49.27
Inter-method agreement
Intra-observer agreement
 Light 1.1 vs. Virtual 1.1 45 18.61 21.70 19.43 − 51.47 61.51 − 23.92, 61.14
 Light 1.1 vs. Virtual 1.2 43 18.11 21.34 15.17 − 21.66 62.17 − 23.71, 59.94
 Light 1.2 vs. Virtual 1.1 38 8.64 23.99 11.33 − 63.45 70 − 38.38, 55.65
 Light 1.2 vs. Virtual 1.2 40 3.14 26.61 7.48 − 70.18 62.33 − 49.01, 55.29
 Light 2 vs. Virtual 2 35 21.73 25.57 15.51 − 34.90 78.03 − 28.39, 71.85
Inter-observer agreement
 Light 1.1 vs. Virtual 2 39 21.05 26.27 12.71 − 34.90 76.36 − 30.43, 72.54
 Light 1.2 vs. Virtual 2 41 11.97 19.06 10.00 − 34.90 59.4 − 25.38, 49.33
 Light 2 vs. Virtual 1.1 41 19.38 22.37 22.37 − 54.47 59.38 − 24.46, 63.21
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Figure 2.  Reproducibility plot for all characteristics evaluated on the core and slide level. Note: Mean inter-
observer agreement refers to the mean of the agreements between the Reviewer 1.1 vs. Reviewer 2 and Reviewer 
1.2. vs. Reviewer 2. LM light microscopy; VM virtual microscopy; GGs Gleason Grade Groups; GS Gleason 
score; PNI perineural invasion; PAH Postatrophic hyperplasia; HGPIN High-grade prostatic intraepithelial 
neoplasia; infl Inflammation; ca carcinoma.
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poor, with average differences close to 0 for both methods but with wide limits of agreement (Table 3, Supple-
mentary Fig. S10).
Interchangeability. Inter‑method, intra‑observer agreement. The core length was on average 1 mm short-
er, while the tumour length was 1 mm longer, when measured by the same reviewer using VM vs. LM, with 
similar limits of agreement for all intra-observer comparisons (Supplementary Figs. S11 and S12). The median 
inter-method intra-observer agreement for the Gleason related characteristics was similar to the average intra-
method intra-observer agreement, indicating interchangeability of LM and VM (Fig. 3). It ranged from mod-
erate to almost perfect (primary Gleason pattern: κw = 0.69–0.88; secondary Gleason pattern: κw = 0.59–0.75; 
GGs: κw = 0.81–0.87) (Supplementary Fig. S13). Similarly, the median inter-method intra-observer agreement 
for the remaining core level characteristics was similar to the average intra-method, intra-observer agreement, 
indicating interchangeability of LM and VM (Fig. 3, Supplementary Fig. S13). However, for most of the slide 
level characteristics, median inter-method intra-observer agreement was lower than the average intra-method 
intra-observer agreement (Fig. 3, Supplementary Fig. S14), probably due to the higher intra-observer agreement 
on VM vs. LM. On average, the percentage of Gleason pattern 4 measured using LM was 3.14–21.73 percentage 
points larger then when using VM, with wide limits of agreement (Table 3, Supplementary Fig. S15).
Inter‑method, inter‑observer agreement. The inter-observer agreement was on average 1 mm shorter for core 
length, and 1 mm longer for tumour length, when measured by the two reviewers using LM vs. VM (Supple-
mentary Figs. S16 and S17). The median inter-method inter-observer agreement for the Gleason related char-
acteristics was similar to the median intra-method, inter-observer agreement, indicating interchangeability of 
VM and LM (Fig. 4). It ranged from moderate to almost perfect (primary Gleason pattern: κw = 0.76–0.88; sec-
ondary Gleason pattern: κw = 0.53–0.77; GGs: κw = 0.81–0.88) (Supplementary Fig. S18). Similarly, median inter-
method inter-observer agreement for the remaining characteristics was similar to the median intra-method 
inter-observer agreement, indicating interchangeability of VM and LM (Fig. 4, Supplementary Figs. S18 and 
S19). The average difference in the percentage of Gleason pattern 4 measured using LM vs. VM was 11.97–21.05 
percentage points, with very wide limits of agreement (Table 3, Supplementary Fig. S20).
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Figure 3.  Interchangeability plot for all characteristics evaluated on the core and slide level (median inter-
method intra-observer agreement vs. mean intra-method intra-observer agreement). Note: Median inter-
method intra-observer agreement refers to the median of the agreements between the Reviewer 1.1 on LM vs. 
VM, Reviewer 1.2 on LM vs. VM and Reviewer 2 on LM vs. VM. Mean intra-method intra-observer agreement 
refers to the mean of the agreements between the Reviewer 1.1 vs. Reviewer 1.2 on LM and on VM. LM, light 
microscopy; VM virtual microscopy; GGs Gleason Grade Groups; GS, Gleason score; PNI Perineural invasion; 
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Discussion
This is the first study with detailed, replicate reviews of the ISUP 2014 Gleason grading system on both LM and 
VM. We found interchangeability of LM and VM, adding further to the body of evidence showing non-inferiority 
of VM compared to LM. Furthermore, on both LM and VM, we found good repeatability and reproducibility 
for all the evaluated histopathological characteristics, except for the percentage of Gleason pattern 4, presence 
of inflammation, HGPIN and postatrophic hyperplasia (PAH). The repeatability and reproducibility for these 
features should be investigated further and improved before they are used in clinical practice.
In line with previous studies, our study shows that VM and LM can be used interchangeably for Gleason 
grading, core length, tumour length and perineural invasion. Previous studies have reported moderate to almost 
perfect inter-method, intra-observer agreement, and moderate to substantial intra-method, inter-observer agree-
ment, for both LM and VM for primary and secondary Gleason pattern, Gleason score, tumour length and 
perineural  invasion6,23–25. We additionally report similar intra-method, intra-observer agreement for primary and 
secondary Gleason pattern, Gleason score and perineural invasion, as well as better agreement for core length and 
tumour length on VM vs. LM. Our study is unique in that we also evaluated the interchangeability of VM and LM 
for cribriform pattern, poorly formed glands, comedonecrosis, percentage of Gleason pattern 4, and intraductal 
and mucinous carcinoma, inflammation, HGPIN and PAH. Even when we did not find good repeatability and/
or reproducibility (i.e. for percentage of Gleason pattern 4, inflammation, HGPIN and PAH), our findings were 
similar on LM and VM, indicating that also for these characteristics LM and VM can be used interchangeably.
In prior studies, Gleason grading reproducibility has typically been evaluated by assessing the inter-observer 
agreement on diagnostic biopsies using LM. The reported agreement varies from no to almost perfect for pri-
mary and secondary Gleason pattern, Gleason score and GGs among general  pathologists3–5,7–9,27–29, and, as in 
our study, from moderate to substantial for Gleason score among  uropathologists3,10,11. Compared to previous 
studies, we observed somewhat better inter-observer agreement for secondary Gleason pattern and the GGs, 
which could be explained by Reviewer 1 and Reviewer 2 having worked together for more than 7 years. The 
intra-observer agreement has been less studied, with few reports showing slightly lower agreement for primary 
and secondary Gleason pattern, and Gleason score on LM than in our  study3,29. The differences between our 
study and previous studies for both the inter- and intra-observer agreement may be due to the use of different 
statistical methods to evaluate agreement, or because many of the previous studies were performed either before 
the ISUP 2005 revision or shortly thereafter.
We found moderate to substantial intra- and inter-observer agreement both within and between LM and VM 
for poorly formed glands, cribriform pattern and comedonecrosis, indicating good repeatability, reproducibility 
and interchangeability of LM and VM for these features. Previous studies report no to substantial inter-observer 
agreement for “poorly formed glands”15,16, poor to substantial agreement for cribriform  pattern15,16, and moderate 
intra-observer agreement for  comedonecrosis17. In the ISUP 2014 revision it was recommended that the percent-
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Figure 4.  Interchangeability plot for all characteristics evaluated on the core and slide level. Note: Median 
intra-method inter-observer agreement refers to the median of the agreements between the Reviewer 1.1 vs. 
Reviewer 2 and Reviewer 1.2 vs. Reviewer 2 on LM and on VM. Median inter-method inter-observer agreement 
refers to the median of the agreements between the Reviewer 1.1 on LM vs. Reviewer 2 on VM, Reviewer 2 on 
LM vs. Reviewer 1.1 on VM, Reviewer 2 on LM vs. Reviewer 1.2 on VM and Reviewer 1.2 on LM vs. Reviewer 
2 on VM. LM, light microscopy; VM virtual microscopy; GGs Gleason Grade Groups; GS Gleason score; PNI 
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agreement using LM is moderate to  substantial16. However, a previous study reported that the average percentage 
of Gleason pattern 4 evaluated using LM is almost twice as large as the VM  estimate30, indicating overestimation 
of the percentage of Gleason pattern 4 on LM. We also found higher average percentage of Gleason pattern 4 
on LM vs. VM. The intra-observer agreement in our study was somewhat better on VM compared to LM. The 
wide limits of agreement, however, indicate either a poor repeatability and reproducibility on both methods or 
a strong influence of outliers given a small sample size used in this analysis. Taken together, previous data and 
our data suggest that the repeatability and reproducibility for percentage Gleason pattern 4 should be further 
investigated and improved before it is used in clinical practice.
To the best of our knowledge, no previous study has evaluated the agreement for intraductal carcinoma, 
mucinous carcinoma, presence of inflammation, HGPIN and PAH in prostate cancer biopsy samples. We found 
moderate to substantial intra- and inter-method, intra-observer agreement for intraductal and mucinous carci-
noma, except for Reviewer 2. The intra-method, inter-observer agreement, however, was not as good, especially 
when VM was used. Given that Reviewer 1 had more experience with VM, the inter-method, intra-observer and 
intra-method, inter-observer agreement could potentially be improved by additional VM training for Reviewer 2. 
Our results also indicate moderate reproducibility for the presence of inflammation, HGPIN and PAH, regardless 
of the method used. The repeatability, however, was better when VM was used. Since all of these features are not 
commonly reported and/or are rare, the guidelines for their assignment are not as uniform as for e.g. Gleason 
 grading31,32. Thus, consensus on their assignment could further improve both repeatability and reproducibility.
The key limitation of this study is that we evaluated agreement only between two uropathologists that have 
also worked together, which may partly explain the generally high inter-observer agreement we observed for 
several key characteristics. Our findings, thus, may not reflect the agreement between general or unrelated 
pathologists. However, this does not affect our key finding of interchangeability of LM and VM as we found that 
the inter-observer, as well as intra-observer, agreement was similar on LM vs. VM, and they were both similar 
to the inter-method agreement. Furthermore, it is likely that unequal training in the use of VM, as well as use 
of small 12.9-inch display on the 2018 iPad Pro, which was used to run VM, could preclude the identification 
of small (e.g., smaller cancer foci) or rare features (e.g., intraductal or mucinous carcinoma). This could explain 
why Reviewer 2 identified less cores with cancer on VM compared with LM. As we did not have information 
on consensus diagnosis, we could not evaluate whether more cores with cancer are missed using LM or VM. 
However, at least one previous study reported that compared with the consensus diagnosis, more pathologists 
missed invasive cancers on LM than on VM, and the inter-observer agreement on invasive cancer was better 
on VM vs.  LM24. Given the small number of slides evaluated in this study (n = 8), this important aspect should 
be further investigated.
Conclusion
Our study confirms that VM and LM can be used interchangeably. In addition, we found good repeatability for 
primary and secondary Gleason pattern, Gleason score, GGs and perineural invasion as well as for the presence 
of poorly formed glands, cribriform pattern and comedonecrosis. The repeatability and/or reproducibility for 
the percentage of Gleason pattern 4 and other less commonly reported features was, however, poor on both LM 
and VM, indicating a lack of a consensus and/or pathologists’ training in assignment of these features. Emphasis 
should be put on improving the repeatability and reproducibility of these features before they are used in clini-
cal practice.
Materials and methods
Study sample. ProMort is a case–control study nested in the National Prostate Cancer Register of Sweden 
(NPCR), a clinical cancer registry containing data on virtually all men in Sweden diagnosed with prostate can-
cer since  199833. In this study, we included a random sample of cases/controls from ProMort (n = 60) diagnosed 
with non-metastatic prostate cancer (i.e., non-M1) between January 1, 1998 and December 31, 2014 in two out 
of Sweden’s 21 counties (n = 25 from Örebro county, and n = 35 from Värmland county). The regional Swedish 
Ethics Review Authority (Etikprövningsmyndigheten) in Stockholm, Sweden approved this study (reference 
number: 2017/1705-32) and the requirement for informed consent was waived. All analyses were performed in 
accordance with relevant guidelines and regulations.
Slide digitalization and managing. The diagnostic biopsy slides from the 60 study members were 
retrieved from the Pathology wards at the Örebro University Hospital, Örebro, Sweden, and Karlstad Central 
Hospital, Karlstad, Sweden, and scanned at Örebro University Hospital using the Pannoramic 250 Flash II digital 
slide scanner (3DHistech Ltd., Budapest, Hungary) with a 40 × objective, yielding images with a resolution of 
0.19 microns/pixel. The original slide labels were replaced with a new study identifier (study ID).
After scanning, the images were uploaded to a VM system developed by the Centre for Advanced Studies, 
Research and Development in Sardinia (CRS4), Pula, Italy. The technical details of the VM system will be pub-
lished in a separate article (under preparation) and a more detailed description is provided in the Supplementary 
methods. In short, the VM system is composed of two integrated components: (1)  ome_seadragon34, a plugin 
for the Open Microscopy Environment Remote Objects (OMERO)  platform35 which enables viewing, handling 
and annotation of the 3DHistech images, and (2) the ProMort Image Management System (https ://githu b.com/
crs4/ProMo rt), a clinical annotation platform which manages the review worklist and the clinical annotation 
process. The ome_seadragon plugin adds Deep Zoom Image format support to the OMERO platform and enables 
interactive mark-up of regions of interest (ROIs) on the slide and automated measurements of marked ROIs (e.g., 
length or area of the ROI). The ProMort Image Management System embeds an ome_seadragon client allowing 
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for user-friendly navigation and clinical annotation of digitalized slides using a dedicated user interface specifi-
cally designed for ProMort.
Both the ome_seadragon client and the ProMort Image Management System are web-based applications 
developed to run on all modern browsers and require no specific hardware or operative system. For this study, the 
pathologists used either a desktop PC, with a 22 inch Olivetti OLISCREEN22 display, running Google Chrome 
browser or a 2018 iPad Pro, with a 12.9 inch display, running Safari browser.
Histopathological review. The histopathological review was performed according to a pre-specified pro-
tocol. To avoid the use of the same study ID in different reviews, a new random identifier was automatically 
assigned to each slide by the ProMort platform worklist manager. The link between this new random ID and the 
study ID was known only to the ProMort worklist manager.
Two genitourinary pathologists (F.G., M.F.) performed the histopathological review according to the WHO 
classification of tumours of the urinary system and male genital organs issued in  201636, following a pre-specified 
protocol, with a minimum washout period of 2 weeks between each review. The first pathologist (Reviewer 1), 
with 11 years of experience (6 years as a dedicated genitourinary pathologist), performed two reviews using LM 
and two reviews using VM, while the second pathologist (Reviewer 2), with 27 years of experience (13 years as a 
dedicated genitourinary pathologist), performed one review using LM and one review using VM. This approach 
allowed us to estimate both the intra- and inter-observer agreement for both LM and VM. Both pathologists had 
been consulted during development of the VM system and were familiar with its functionality. Both pathologists 
were blinded to the original clinical and histopathological information of all slides.
For both LM and VM, the histopathological review started with a quality control of all diagnostic slides. We 
excluded slides that lacked tissue or for quality reasons (Supplementary Table S3). For each core, we recorded 
core length (mm) and presence of cancer. For each core with cancer, we recorded tumour length (mm), primary 
and secondary Gleason pattern, Gleason pattern related characteristics (i.e., poorly formed glands, cribriform 
pattern, comedonecrosis), Gleason Grade Groups (GGs), and presence and absence of perineural invasion, 
intraductal, ductal, hypernephroid and mucinous carcinoma. For cores with Gleason score 7, we measured the 
percentage of Gleason pattern 4 on LM by “eye-balling” (categorized as < 10%, 10–19%, 20–29% etc.14) and on 
VM as the area of Gleason pattern 4 divided by the total tumour area. For each slide (but not for each core), we 
recorded information on the presence or absence of acute, chronic, periglandular, intraglandular and stromal 
inflammation, HGPIN and PAH.
Statistical analyses. We assessed the intra- and inter-observer agreement within each method and between 
the two methods using Cohen’s kappa (κ) for binary  variables37, weighted Cohen’s kappa (κw) with linear weights 
for ordinal  variables38, and Bland and Altman’s limits of agreement for continuous  variables39. For descriptive 
purposes, κ/κw < 0 was considered as no agreement, 0–0.20 slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 
substantial, and 0.81–1 almost perfect  agreement40.
Agreement was evaluated on the core level for all characteristics recorded on the core level and on the slide 
level for characteristics recorded only on the slide level. For characteristics typically reported on the case level 
(i.e., the primary and secondary Gleason pattern, Gleason score, GGs, total core length, total tumour length, 
and perineural invasion), we also evaluated the case level agreement.
Analyses were conducted in Stata (version 12.1, StataCorp, College Station, Texas, USA).
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